20
Participants
Start Date
March 29, 2023
Primary Completion Date
December 31, 2026
Study Completion Date
December 31, 2028
Atezolizumab
Atezolizumab is a monoclonal antibody that belongs to a class of drugs that bind to either the programmed death-receptor 1 (PD-1) or the PD-ligand 1 (PD-L1), blocking the PD-1/PD-L1 pathway,
Bevacizumab
Bevacizumab is a tumor-starving (anti-angiogenic) therapy. Avastin is designed to block a protein called vascular endothelial growth factor, or VEGF.
RECRUITING
Georgetown Lombardi Comprehensive Cancer Center, Washington D.C.
RECRUITING
Medstar Washington Hospital Center, Washington D.C.
RECRUITING
John Theurer Cancer Center at Hackensack University Medical Center, Hackensack
Collaborators (2)
Genentech, Inc.
INDUSTRY
Natera, Inc.
INDUSTRY
Georgetown University
OTHER